Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 31;13:980526. doi: 10.3389/fimmu.2022.980526

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Faissner, Heitmann, Plaza-Sirvent, Trendelenburg, Ceylan, Motte, Bessen, Urlaub, Watzl, Overheu, Reinacher-Schick, Hellwig, Pfaender, Schmitz and Gold

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Ofa treated patients exhibit a stronger response of IFN-γ⁺ activated T helper cells. Peripheral blood mononuclear cells (PBMCs) of ofatumumab treated MS patients (Ofa) and healthy controls (HC) were collected 4-13 weeks following the third vaccination against SARS-CoV-2 and restimulated with a SARS-CoV-2 peptide pool following immunophenotyping via FACS. (A) Frequencies of CD4⁺ IFN-γ⁺ T cells were significantly higher in the Ofa group compared to HC (p<0.01). (B) The expression of IL-2 (p=0.2343), (C) IFN-γ and IL-2 (p=0.6513), (D) IL-4 (p=0.2775) and (E) IL-17 (p=0.2110) in CD4⁺ T helper cells did not differ between respective groups. Data were analyzed with a two-tailed Mann-Whitney U test. n=10 Ofa, n=9 HC. **p < 0.01.